Roldo Marta, Barbu Eugen, Brown James F, Laight David W, Smart John D, Tsibouklis John
University of Portsmouth, School of Pharmacy and Biomedical Sciences, St Michael's Building, White Swan Road, Portsmouth PO1 2DT, UK.
Expert Opin Drug Deliv. 2007 Sep;4(5):547-60. doi: 10.1517/17425247.4.5.547.
Azo compounds have the potential to act as drug carriers that facilitate the selective release of therapeutic agents to the colon, and also to effect the oral administration of those macromolecular drugs that require colon-specific drug delivery. With some further research-driven refinements, these materials may lead to more efficient treatments for local conditions, such as colonic cancer or inflammatory bowel disease. This article provides an overview of the azo-based systems developed to date, identifies the requirements for an ideal carrier, and highlights the directions for further developments in the field of azo group-facilitated colonic delivery.
偶氮化合物有潜力作为药物载体，促进治疗剂向结肠的选择性释放，还能实现那些需要结肠特异性给药的大分子药物的口服给药。通过一些进一步的研究驱动改进，这些材料可能会为局部病症，如结肠癌或炎症性肠病带来更有效的治疗方法。本文概述了迄今为止开发的基于偶氮的系统，确定了理想载体的要求，并突出了偶氮基团促进结肠给药领域的进一步发展方向。
